{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:20:32Z","timestamp":1793996432874,"version":"4.8.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05311-7","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:36:24Z","timestamp":1779806184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrative advances in biomarker-driven prostate cancer management from genomic discovery to precision oncology"],"prefix":"10.1007","volume":"17","author":[{"given":"Priyanka","family":"Ramesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Shree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Stanley","family":"Balraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"3","key":"5311_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5311_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63\u201389.","journal-title":"World J Oncol"},{"key":"5311_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231222389","volume":"23","author":"AS Balraj","year":"2024","unstructured":"Balraj AS, Muthamilselvan S, Raja R, Palaniappan A. PRADclass: Hybrid Gleason grade-informed computational strategy identifies consensus biomarker features predictive of aggressive prostate adenocarcinoma. Technol Cancer Res Treat. 2024;23:15330338231222388.","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"5311_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JU.0000000000003721","volume":"211","author":"ED Crawford","year":"2024","unstructured":"Crawford ED, Hafron JM, Debruyne F, Wallis C, Chang S, Garnick MB. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist. J Urol. 2024;211(1):63\u201370.","journal-title":"J Urol"},{"key":"5311_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-016-0478-2","author":"J Gordetsky","year":"2016","unstructured":"Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol. 2016. https:\/\/doi.org\/10.1186\/s13000-016-0478-2.","journal-title":"Diagn Pathol"},{"key":"5311_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13040628","volume":"13","author":"K Sopyllo","year":"2021","unstructured":"Sopyllo K, Erickson AM, Mirtti T. Grading evolution and contemporary prognostic biomarkers of clinically significant prostate cancer. Cancers. 2021;13:1\u201321.","journal-title":"Cancers"},{"issue":"2","key":"5311_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.clgc.2019.10.022","volume":"18","author":"L Chapman","year":"2020","unstructured":"Chapman L, Ledet EM, Barata PC, Cotogno P, Manogue C, Moses M, et al. TP53 gain-of-function mutations in circulating tumor DNA in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2020;18(2):148\u201354.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"5311_CR8","doi-asserted-by":"publisher","first-page":"e13827","DOI":"10.1016\/j.heliyon.2023.e13827","volume":"9","author":"H Zhu","year":"2023","unstructured":"Zhu H, Ding Y, Huang H, Lin Q, Chen W, Yu Z. Prognostic value of genomic mutations in metastatic prostate cancer. Heliyon. 2023;9(3):e13827.","journal-title":"Heliyon"},{"issue":"3","key":"5311_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","volume":"83","author":"A Loehr","year":"2023","unstructured":"Loehr A, Hussain A, Patnaik A, Bryce AH, Castellano D, Font A, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. 2023;83(3):200\u20139.","journal-title":"Eur Urol"},{"issue":"2","key":"5311_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","volume":"79","author":"A Neeb","year":"2021","unstructured":"Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, et al. Advanced prostate cancer with ATM loss: PARP and ATR inhibitors. Eur Urol. 2021;79(2):200\u201311.","journal-title":"Eur Urol"},{"issue":"11","key":"5311_CR11","doi-asserted-by":"publisher","first-page":"e4557","DOI":"10.1016\/j.urolonc.2023.09.014","volume":"41","author":"M Al-Toubat","year":"2023","unstructured":"Al-Toubat M, Serrano S, Elshafei A, Koul K, Feibus AH, Balaji KC. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis. Urol Oncol. 2023;41(11):e4557\u201345515.","journal-title":"Urol Oncol"},{"issue":"6","key":"5311_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100146","volume":"36","author":"R Mehra","year":"2023","unstructured":"Mehra R, Shah T, Liu CJ, Plouffe KR, Wang X, Mannan R, et al. Highly recurrent IDH1 mutations in prostate cancer with psammomatous calcification. Mod Pathol. 2023;36(6):100146.","journal-title":"Mod Pathol"},{"key":"5311_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-168","volume":"7","author":"M Krypuy","year":"2007","unstructured":"Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ, DeFazio A, Fox SB, et al. High resolution melting for mutation scanning of TP53 exons 5\u20138. BMC Cancer. 2007;7:168.","journal-title":"BMC Cancer"},{"issue":"12","key":"5311_CR14","first-page":"4445","volume":"31","author":"P Pepe","year":"2011","unstructured":"Pepe P, Aragona F. PCA3 Score vs PSA free\/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res. 2011;31(12):4445\u20139.","journal-title":"Anticancer Res"},{"issue":"4","key":"5311_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1590\/S1677-55382012000400008","volume":"38","author":"P Pepe","year":"2012","unstructured":"Pepe P, Fraggetta F, Galia A, Skonieczny G, Aragona F. {PCA3} score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? Int Braz J Urol. 2012;38(4):489\u201395.","journal-title":"Int Braz J Urol"},{"key":"5311_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.euros.2023.04.003","volume":"52","author":"R Grochot","year":"2023","unstructured":"Grochot R, Carreira S, Miranda S, Figueiredo I, Bertan C, Rekowski J, et al. Germline ATM mutations detected by somatic DNA sequencing in lethal prostate cancer. Eur Urol Open Sci. 2023;52:72\u20138.","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"5311_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ijrobp.2022.12.006","volume":"115","author":"P Sutera","year":"2023","unstructured":"Sutera P, Deek MP, Van der Eecken K, Shetty AC, Chang JH, Hodges T, et al. WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer. Int J Radiat Oncol Biol Phys. 2023;115(5):1095\u2013101.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5311_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2023.41.6_suppl.229","volume":"41","author":"A Broderick","year":"2023","unstructured":"Broderick A, Li J, Chu A, et al. Clinical implications of Wnt signaling alterations in patients (pts) with advanced prostate cancer (aPC). J Clin Oncol. 2023;41:229\u2013229.","journal-title":"J Clin Oncol"},{"key":"5311_CR19","first-page":"100","volume":"6","author":"H Nasimi","year":"2023","unstructured":"Nasimi H, Madsen JS, Zedan AH, et al. Protein biomarker detection in prostate cancer: A comprehensive review of electrochemical biosensors. Sens Actuators Rep. 2023;6:100\u201368.","journal-title":"Sens Actuators Rep"},{"key":"5311_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omto.2023.07.004","volume":"30","author":"M Alahdal","year":"2023","unstructured":"Alahdal M, Perera RA, Moschovas MC, Patel V, Perera RJ. Current advances of liquid biopsies in prostate cancer: Molecular biomarkers. Mol Ther oncolytics. 2023;30:27\u201338.","journal-title":"Mol Ther oncolytics"},{"issue":"1","key":"5311_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.euf.2022.09.002","volume":"9","author":"CU Lee","year":"2023","unstructured":"Lee CU, Cho E, Lee J, Lim JE, Chung JH, Song W, et al. Chromosomal instability in cell-free DNA as a prognostic biomarker of metastatic hormone-sensitive prostate cancer treated with androgen deprivation therapy. Eur Urol Focus. 2023;9(1):89\u201395.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"5311_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06817-1","volume":"20","author":"ET Miller","year":"2020","unstructured":"Miller ET, You S, Cadaneanu RM, Kim M, Yoon J, Liu ST, et al. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. BMC Cancer. 2020;20(1):398.","journal-title":"BMC Cancer"},{"key":"5311_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104212","volume":"81","author":"R Sawpari","year":"2023","unstructured":"Sawpari R, Samanta S, Banerjee J, Das S, Dash SS, Ahmed R, et al. Recent advances and futuristic potentials of nano-tailored doxorubicin for prostate cancer therapy. J Drug Deliv Sci Technol. 2023;81: 104212.","journal-title":"J Drug Deliv Sci Technol"},{"key":"5311_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/0284186X.2010.542174","volume":"50","author":"F Shahrokh","year":"2011","unstructured":"Shahrokh F. Shariat1, Axel Semjonow2, Hans Lilja3, Caroline Savage4, Andrew J. Vickers4 and AB. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011;50:61\u201375.","journal-title":"Acta Oncol"},{"issue":"4","key":"5311_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/pcan.2010.29","volume":"13","author":"P Pepe","year":"2010","unstructured":"Pepe P, Aragona F. Incidence of insignificant prostate cancer using free\/total {PSA}: results of a case-finding protocol on 14,453 patients. Prostate Cancer Prostatic Dis. 2010;13(4):316\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"5311_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.bbamcr.2018.06.016","volume":"1866","author":"CE Nunes-Xavier","year":"2019","unstructured":"Nunes-Xavier CE, Mingo J, L\u00f3pez JI, Pulido R. The role of protein tyrosine phosphatases in prostate cancer biology. Biochimica et Biophysica Acta (BBA). 2019;1866(1):102\u201313.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"5311_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154243","volume":"241","author":"CE Nunes-Xavier","year":"2023","unstructured":"Nunes-Xavier CE, Emaldi M, Guldvik IJ, Ramberg H, Task\u00e9n KA, M\u00e6landsmo GM, et al. Correlation of expression of major vault protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer. Pathol Res Pract. 2023;241:154243.","journal-title":"Pathol Res Pract"},{"issue":"4","key":"5311_CR28","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3892\/ijo.2017.4093","volume":"51","author":"GA Cardama","year":"2017","unstructured":"Cardama GA, Gonzalez N, Maggio J, Menna PL, Gomez DE. Rho GTPases as therapeutic targets in cancer (Review). Int J Oncol. 2017;51(4):1025\u201334.","journal-title":"Int J Oncol"},{"key":"5311_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153897","author":"R Opeyemi Bello","year":"2023","unstructured":"Opeyemi Bello R, Willis-Powell L, James O, Sharma A, Marsh E, Ellis L, et al. Does Human Papillomavirus play a causative role in prostate cancer? A systematic review using Bradford Hill\u2019s criteria. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153897.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"5311_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14737159.2019.1675515","volume":"20","author":"E Boerrigter","year":"2020","unstructured":"Boerrigter E, Groen LN, Van Erp NP, Verhaegh GW, Schalken JA. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Rev Mol Diagn. 2020;20(2):219\u201330.","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"5311_CR31","first-page":"617","volume":"31","author":"F Urabe","year":"2024","unstructured":"Urabe F, Sumiyoshi T, Tashiro K, Goto T, Kimura T, Kobayashi T. Prostate cancer and liquid biopsies: clinical applications and challenges. Int J Urol Off J Japanese Urol Assoc. 2024;31(6):617\u201326.","journal-title":"Int J Urol Off J Japanese Urol Assoc"},{"key":"5311_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.matbio.2018.08.004","volume":"77","author":"SR Krishn","year":"2019","unstructured":"Krishn SR, Singh A, Bowler N, Duffy AN, Friedman A, Fedele C, et al. Prostate cancer sheds the \u03b1v\u03b23 integrin in vivo through exosomes. Matrix Biol. 2019;77:41\u201357.","journal-title":"Matrix Biol"},{"key":"5311_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.679527","volume":"9","author":"Z Gao","year":"2021","unstructured":"Gao Z, Pang B, Li J, Gao N, Fan T, Li Y. Emerging role of exosomes in liquid biopsy for monitoring prostate cancer invasion and metastasis. Front Cell Dev Biol. 2021;9:679527.","journal-title":"Front Cell Dev Biol"},{"key":"5311_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071728","author":"F Ionescu","year":"2022","unstructured":"Ionescu F, Zhang J, Wang L. Clinical applications of liquid biopsy in prostate cancer: from screening to predictive biomarker. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14071728.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"5311_CR35","doi-asserted-by":"publisher","first-page":"14408","DOI":"10.3390\/cimb46120864","volume":"46","author":"C Roidos","year":"2024","unstructured":"Roidos C, Anastasiadis A, Tsiakaras S, Loutradis C, Baniotis P, Memmos D, et al. Integration of genomic tests in prostate cancer care: implications for clinical practice and patient outcomes. Curr Issues Mol Biol. 2024;46(12):14408\u201321.","journal-title":"Curr Issues Mol Biol"},{"issue":"8","key":"5311_CR36","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41416-022-01881-9","volume":"127","author":"B Trujillo","year":"2022","unstructured":"Trujillo B, Wu A, Wetterskog D, Attard G. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br J Cancer. 2022;127(8):1394\u2013402.","journal-title":"Br J Cancer"},{"issue":"1","key":"5311_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bju.16457","volume":"135","author":"PKF Chiu","year":"2025","unstructured":"Chiu PKF, Liu AQ, Lau SY, Teoh JYC, Ho CC, Yee CH, et al. A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort. BJU Int. 2025;135(1):71\u20137.","journal-title":"BJU Int"},{"key":"5311_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biology13100762","author":"S Hachem","year":"2024","unstructured":"Hachem S, Yehya A, El Masri J, Mavingire N, Johnson JR, Dwead AM, et al. Contemporary update on clinical and experimental prostate cancer biomarkers: a multi-omics-focused approach to detection and risk stratification. Biology (Basel). 2024. https:\/\/doi.org\/10.3390\/biology13100762.","journal-title":"Biology (Basel)"},{"key":"5311_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040296","author":"K Bal\u00e1zs","year":"2021","unstructured":"Bal\u00e1zs K, Antal L, S\u00e1fr\u00e1ny G, Lumniczky K. Blood-derived biomarkers of diagnosis, prognosis and therapy response in prostate cancer patients. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11040296.","journal-title":"J Pers Med"},{"issue":"4","key":"5311_CR40","first-page":"231","volume":"17","author":"B Konety","year":"2015","unstructured":"Konety B, Zappala SM, Parekh DJ, Osterhout D, Schock J, Chudler RM, et al. The 4Kscore\\textregistered{}Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. Rev Urol. 2015;17(4):231\u201340.","journal-title":"Rev Urol"},{"issue":"1","key":"5311_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41391-024-00840-0","volume":"28","author":"HS Robinson","year":"2025","unstructured":"Robinson HS, Lee SS, Barocas DA, Tosoian JJ. Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer. Prostate Cancer Prostatic Dis. 2025;28(1):45\u201355.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"5311_CR42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41391-021-00456-8","volume":"25","author":"E Margolis","year":"2022","unstructured":"Margolis E, Brown G, Partin A, Carter B, McKiernan J, Tutrone R, et al. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis. 2022;25(2):296\u2013301.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"5311_CR43","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.urolonc.2012.05.002","volume":"31","author":"CG Ramos","year":"2012","unstructured":"Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and\/or suspicious digital rectal examination. First Latin American experience. Urol Oncol. 2012;31(8):1522\u20136.","journal-title":"Urol Oncol"},{"issue":"3","key":"5311_CR44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/02813432.2020.1802139","volume":"38","author":"E Viste","year":"2020","unstructured":"Viste E, Vinje CA, Lid TG, Skeie S, Evjen-Olsen \u00d8, Nordstr\u00f6m T, et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. Scand J Prim Health Care. 2020;38(3):315\u201322.","journal-title":"Scand J Prim Health Care"},{"issue":"2","key":"5311_CR45","doi-asserted-by":"publisher","first-page":"e0285745","DOI":"10.1371\/journal.pone.0285745","volume":"19","author":"H Wu","year":"2024","unstructured":"Wu H, Wu Y, He P, Liang J, Xu X, Ji C. A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer. PLoS ONE. 2024;19(2):e0285745.","journal-title":"PLoS ONE"},{"issue":"9","key":"5311_CR46","first-page":"497","volume":"9","author":"L Legisi","year":"2016","unstructured":"Legisi L, DeSa E, Qureshi MN. Use of the prostate core Mitomic Test in repeated biopsy decision-making: real-world assessment of clinical utility in a multicenter patient population. Am Health Drug Benefits. 2016;9(9):497\u2013502.","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"5311_CR47","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.eururo.2020.12.037","volume":"79","author":"I Casanova-Salas","year":"2021","unstructured":"Casanova-Salas I, Athie A, Boutros PC, Del Re M, Miyamoto DT, Pienta KJ, et al. Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer. Eur Urol. 2021;79(6):762\u201371.","journal-title":"Eur Urol"},{"issue":"3","key":"5311_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101383","volume":"9","author":"E Polymeri","year":"2024","unstructured":"Polymeri E, Johnsson \u00c5A, Enqvist O, Ul\u00e9n J, Pettersson N, Nordstr\u00f6m F, et al. Artificial intelligence-based organ delineation for radiation treatment planning of prostate cancer on computed tomography. Adv Radiat Oncol. 2024;9(3):101383.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"5311_CR49","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1007\/s00259-023-06555-z","volume":"51","author":"E Jafari","year":"2024","unstructured":"Jafari E, Zarei A, Dadgar H, Keshavarz A, Manafi-Farid R, Rostami H, et al. A convolutional neural network\u2013based system for fully automatic segmentation of whole-body [68Ga]Ga-PSMA PET images in prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51(5):1476\u201387. https:\/\/doi.org\/10.1007\/s00259-023-06555-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"5311_CR50","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2214\/AJR.19.22254","volume":"214","author":"DK Lee","year":"2020","unstructured":"Lee DK, Sung DJ, Kim CS, Heo Y, Lee JY, Park BJ, et al. Three-dimensional convolutional neural network for prostate MRI segmentation and comparison of prostate volume measurements by use of artificial neural network and ellipsoid formula. AJR Am J Roentgenol. 2020;214(6):1229\u201338.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"5311_CR51","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00120-023-02064-x","volume":"62","author":"S Ursprung","year":"2023","unstructured":"Ursprung S, Herrmann J, Nikolaou K, Harland N, Bedke J, Seith F, et al. Multiparametric MRI of the prostate: requirements and principles regarding diagnostic reporting. Urologie. 2023;62(5):449\u201358.","journal-title":"Urologie"},{"key":"5311_CR52","doi-asserted-by":"crossref","unstructured":"Rouvi\u00e8re O, Souchon R, Lartizien C, Mansuy A, Magaud L, Colom M et al. Detection of ISUP\u2009\u2265\u20092 prostate cancers using multiparametric MRI: prospective multicentre assessment of the non-inferiority of an artificial intelligence system as compared to the PI-RADS V.2.1 score (CHANGE study). BMJ Open. 2022;12(2).","DOI":"10.1136\/bmjopen-2021-051274"},{"key":"5311_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24162878","author":"A Ghosh","year":"2019","unstructured":"Ghosh A, Woolum K, Kothandaraman S, Tweedle MF, Kumar K. Stability evaluation and stabilization of a gastrin-releasing peptide receptor (GRPR) targeting imaging pharmaceutical. Molecules. 2019. https:\/\/doi.org\/10.3390\/molecules24162878.","journal-title":"Molecules"},{"key":"5311_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemolab.2023.104752","volume":"234","author":"E Mustorgi","year":"2023","unstructured":"Mustorgi E, Durante C, Malegori C, Greco P, Bartoletti R, Cocchi M, et al. An analytical approach based on excitation-emission fluorescence spectroscopy and chemometrics for the screening of prostate cancer through urine analysis: A proof\u2013of\u2013concept study. Chemom Intell Lab Syst. 2023;234: 104752.","journal-title":"Chemom Intell Lab Syst"},{"key":"5311_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16030299","author":"RH Wallimann","year":"2024","unstructured":"Wallimann RH, Hensinger H, M\u00fcller C, Schibli R, Kneuer R, Schindler P. Liquid chromatography ICP-MS to assess the stability of (175)Lu- and (nat)Ga-based tumor-targeting agents towards the development of (177)Lu- and (68)Ga-labeled radiopharmaceuticals. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16030299.","journal-title":"Pharmaceutics"},{"key":"5311_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2023.137771","volume":"316","author":"JM Huizenga","year":"2023","unstructured":"Huizenga JM, Semprini L. Fluorescent spectroscopy paired with parallel factor analysis for quantitative monitoring of phenanthrene biodegradation and metabolite formation. Chemosphere. 2023;316:137771.","journal-title":"Chemosphere"},{"issue":"Suppl 1","key":"5311_CR57","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.acra.2023.06.011","volume":"30","author":"Y Qiu","year":"2023","unstructured":"Qiu Y, Liu YF, Shu X, Qiao XF, Ai GY, He XJ. Peritumoral Radiomics Strategy Based on Ensemble Learning for the Prediction of Gleason Grade Group of Prostate Cancer. Acad Radiol. 2023;30(Suppl 1):S1\u201313.","journal-title":"Acad Radiol"},{"key":"5311_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.nucmedbio.2019.01.003","volume":"68\u201369","author":"O Schillaci","year":"2019","unstructured":"Schillaci O, Scimeca M, Trivigno D, Chiaravalloti A, Facchetti S, Anemona L, et al. Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. Nucl Med Biol. 2019;68\u201369:66\u201379.","journal-title":"Nucl Med Biol"},{"key":"5311_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13213350","author":"JY Chen","year":"2023","unstructured":"Chen JY, Wang PY, Liu MZ, Lyu F, Ma MW, Ren XY, et al. Biomarkers for prostate cancer: From diagnosis to treatment. Diagnostics. 2023. https:\/\/doi.org\/10.3390\/diagnostics13213350.","journal-title":"Diagnostics"},{"issue":"3","key":"5311_CR60","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/elsc.201800093","volume":"19","author":"Z Akbari Jonous","year":"2019","unstructured":"Akbari Jonous Z, Shayeh JS, Yazdian F, Yadegari A, Hashemi M, Omidi M. An electrochemical biosensor for prostate cancer biomarker detection using graphene oxide-gold nanostructures. Eng Life Sci. 2019;19(3):206\u201316.","journal-title":"Eng Life Sci"},{"issue":"12","key":"5311_CR61","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1021\/jacsau.4c00989","volume":"4","author":"Y Cao","year":"2024","unstructured":"Cao Y, Xia J, Li L, Zeng Y, Zhao J, Li G. Electrochemical biosensors for cancer diagnosis: Multitarget analysis to present molecular characteristics of tumor heterogeneity. JACS Au. 2024;4(12):4655\u201372.","journal-title":"JACS Au"},{"issue":"2","key":"5311_CR62","volume":"95","author":"P Pepe","year":"2023","unstructured":"Pepe P, Pepe L, Tamburo M, Marletta G, Savoca F, Pennisi M, et al. {68Ga-PSMA} {PET\/CT} evaluation in men enrolled in prostate cancer active surveillance. Arch Ital Urol Androl. 2023;95(2):11322.","journal-title":"Arch Ital Urol Androl"},{"key":"5311_CR63","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/eng4010022","volume":"4","author":"S Takita","year":"2023","unstructured":"Takita S, Nabok A, Lishchuk A, Mussa MH, Smith D. Enhanced performance electrochemical biosensor for detection of prostate cancer biomarker PCA3 using specific aptamer. Eng. 2023;4:367\u201379.","journal-title":"Eng"},{"key":"5311_CR64","volume":"12","author":"SJ Malode","year":"2022","unstructured":"Malode SJ, Shetti NP. New generation biomarkers for the detection of prostate cancer. Biosens Bioelectron X. 2022;12: 100250.","journal-title":"Biosens Bioelectron X"},{"key":"5311_CR65","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241290029","volume":"23","author":"P Agbetuyi-Tayo","year":"2024","unstructured":"Agbetuyi-Tayo P, Gbadebo M, Rotimi OA, Rotimi SO. Advancements in biomarkers of prostate cancer: a review. Technol Cancer Res Treat. 2024;23:15330338241290028.","journal-title":"Technol Cancer Res Treat"},{"key":"5311_CR66","doi-asserted-by":"crossref","unstructured":"Adamaki M, Zoumpourlis V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacology and Therapeutics. Volume 228. Elsevier Inc.; 2021.","DOI":"10.1016\/j.pharmthera.2021.107932"},{"issue":"1","key":"5311_CR67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12967-022-03860-3","volume":"21","author":"P Liu","year":"2023","unstructured":"Liu P, Wang W, Wang F, Fan J, Guo J, Wu T, et al. Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer. J Transl Med. 2023;21(1):40.","journal-title":"J Transl Med"},{"key":"5311_CR68","doi-asserted-by":"publisher","first-page":"104593","DOI":"10.1016\/j.jddst.2023.104593","volume":"85","author":"S Shahrukh","year":"2023","unstructured":"Shahrukh S, Jain N, Shah S, Famta P, Srinivasarao DA, Khatri DK, et al. Aptamer guided nanomedicine strategies in prostate cancer: Targeting and diagnosis. J Drug Deliv Sci Technol. 2023;85:104593.","journal-title":"J Drug Deliv Sci Technol"},{"key":"5311_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117553","volume":"549","author":"F Amaro","year":"2023","unstructured":"Amaro F, Carvalho M, Bastos de L M, Guedes de Pinho P, Pinto J. Metabolic signature biomarkers for predicting the recurrence of urological cancers. Clin Chim Acta. 2023;549:117553.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"5311_CR70","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","volume":"25","author":"T Kulasegaran","year":"2024","unstructured":"Kulasegaran T, Oliveira N. Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Curr Treat Options Oncol. 2024;25(7):914\u201331.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"5311_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/OP.21.00206","volume":"18","author":"N Sayegh","year":"2022","unstructured":"Sayegh N, Swami U, Agarwal N. Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncol Pract. 2022;18(1):45\u201355.","journal-title":"JCO Oncol Pract"},{"issue":"45","key":"5311_CR72","doi-asserted-by":"publisher","first-page":"13194","DOI":"10.1021\/acs.langmuir.1c01370","volume":"37","author":"K De","year":"2021","unstructured":"De K. Decapeptide modified doxorubicin loaded solid lipid nanoparticles as targeted drug delivery system against prostate cancer. Langmuir. 2021;37(45):13194\u2013207.","journal-title":"Langmuir"},{"key":"5311_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01436","volume":"10","author":"K Li","year":"2019","unstructured":"Li K, Zhan W, Chen Y, Jha RK, Chen X. Docetaxel and doxorubicin codelivery by nanocarriers for synergistic treatment of prostate cancer. Front Pharmacol. 2019;10:1436.","journal-title":"Front Pharmacol"},{"key":"5311_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(23)01153-3","volume":"83","author":"E Mazzone","year":"2023","unstructured":"Mazzone E, Gandaglia G, Stabile A, et al. Tailoring the optimal use of androgen-deprivation therapy concomitant to post-operative radiotherapy among men with pN1 prostate cancer. Long-term results of a large, single institution series. Eur Urol. 2023;83:1615.","journal-title":"Eur Urol"},{"key":"5311_CR75","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/S2666-1683(20)30051-3","volume":"19","author":"M Bada","year":"2020","unstructured":"Bada M, De Concilio B, Zeccolini G, Mazzon G, Justich M, Celia A. Tailored therapy in prostate cancer is the new era: Retrospective, monocentric Italian analysis between radiotherapy cyber-knife versus robot assisted radical prostatectomy in low-intermediate risk patients. Eur Urol Open Sci. 2020;19:e57.","journal-title":"Eur Urol Open Sci"},{"issue":"11","key":"5311_CR76","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","volume":"65","author":"V Murthy","year":"2024","unstructured":"Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, et al. Efficacy and toxicity of [(177)Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. Expanded-Access Program and comparisons with Phase 3 VISION Data. J Nucl Med. 2024;65(11):1740\u20134.","journal-title":"J Nucl Med"},{"issue":"1","key":"5311_CR77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2967\/jnumed.124.268807","volume":"66","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Koll F, Hoeh B, Humke C, Siech C, Mader N, et al. Real-world comparison of Cabazitaxel versus (177)Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer. J Nucl Med. 2025;66(1):61\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"5311_CR78","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","volume":"45","author":"MP Yadav","year":"2020","unstructured":"Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, et al. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med. 2020;45(1):19\u201331.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"5311_CR79","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","volume":"7","author":"M Kafka","year":"2024","unstructured":"Kafka M, Horninger A, di Santo G, Virgolini I, Neuwirt H, Unterrainer LM, et al. Real-world Outcomes and Predictive Biomarkers for (177)Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Gr. Eur Urol Oncol. 2024;7(3):421\u20139.","journal-title":"Eur Urol Oncol"},{"key":"5311_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102818","volume":"130","author":"E Akkus","year":"2024","unstructured":"Akkus E, Arslan \u00c7, \u00dcr\u00fcn Y. Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: insights and perspectives. Cancer Treat Rev. 2024;130:102818.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"5311_CR81","doi-asserted-by":"publisher","first-page":"769","DOI":"10.5534\/wjmh.220200","volume":"41","author":"K Hatano","year":"2023","unstructured":"Hatano K, Nonomura N. Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. World J Mens Health. 2023;41(4):769\u201384.","journal-title":"World J Mens Health"},{"issue":"3","key":"5311_CR82","first-page":"241","volume":"13","author":"M Yousefnezhad","year":"2023","unstructured":"Yousefnezhad M, Davaran S, Babazadeh M, Akbarzadeh A, Pazoki-Toroudi H. PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: a combination therapy for prostate cancer using a drug repurposing strategy. Bioimpacts. 2023;13(3):241\u201353.","journal-title":"Bioimpacts"},{"issue":"12","key":"5311_CR83","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.urolonc.2020.06.003","volume":"38","author":"KK Shukla","year":"2020","unstructured":"Shukla KK, Misra S, Sankanagoudar S, Sharma H, Choudhary GR, Pareek P, et al. Recent scenario of long non-coding RNAs as a diagnostic and prognostic biomarkers of prostate cancer. Urol Oncol. 2020;38(12):918\u201328.","journal-title":"Urol Oncol"},{"key":"5311_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113649","volume":"155","author":"R Khan","year":"2022","unstructured":"Khan R, Arshad F, Hassan IU, Naikoo GA, Pedram MZ, Zedegan MS, et al. Advances in nanomaterial-based immunosensors for prostate cancer screening. Biomed Pharmacother. 2022;155:113649.","journal-title":"Biomed Pharmacother"},{"key":"5311_CR85","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fchem.2019.00147","volume":"7","author":"AF Quintero-Jaime","year":"2019","unstructured":"Quintero-Jaime AF, Berenguer-Murcia \u00c1, Cazorla-Amor\u00f3s D, Morall\u00f3n E. Carbon Nanotubes Modified With Au for Electrochemical Detection of Prostate Specific Antigen: Effect of Au Nanoparticle Size Distribution. Front Chem. 2019;7:147.","journal-title":"Front Chem"},{"issue":"10","key":"5311_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101199","volume":"4","author":"D Sridaran","year":"2023","unstructured":"Sridaran D, Bradshaw E, DeSelm C, Pachynski R, Mahajan K, Mahajan NP. Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach. Cell Rep Med. 2023;4(10):101199.","journal-title":"Cell Rep Med"},{"issue":"1","key":"5311_CR87","doi-asserted-by":"publisher","first-page":"32","DOI":"10.12998\/wjcc.v12.i1.32","volume":"12","author":"Z Song","year":"2024","unstructured":"Song Z, Zhou Q, Zhang JL, Ouyang J, Zhang ZY. Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J Clin cases. 2024;12(1):32\u201341.","journal-title":"World J Clin cases"},{"key":"5311_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtemb.2022.126992","volume":"72","author":"Y Yang","year":"2022","unstructured":"Yang Y, McDonald AC, Wang X, Pan Y, Wang M. Arsenic exposures and prostate cancer risk: a multilevel meta-analysis. J Trace Elem Med Biol. 2022;72:126992.","journal-title":"J Trace Elem Med Biol"},{"issue":"2","key":"5311_CR89","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12032-023-02266-5","volume":"41","author":"AG Mukherjee","year":"2024","unstructured":"Mukherjee AG, Gopalakrishnan AV. Arsenic-induced prostate cancer: an enigma. Med Oncol. 2024;41(2):50.","journal-title":"Med Oncol"},{"issue":"1155","key":"5311_CR90","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/bjr\/tqad066","volume":"97","author":"S Mukherjee","year":"2024","unstructured":"Mukherjee S, Papadopoulos D, Chari N, Ellis D, Charitopoulos K, Charitopoulos I, et al. High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model. Br J Radiol. 2024;97(1155):574\u201382.","journal-title":"Br J Radiol"},{"key":"5311_CR91","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.omtn.2019.09.008","volume":"18","author":"Q Wa","year":"2019","unstructured":"Wa Q, Huang S, Pan J, Tang Y, He S, Fu X, et al. miR-204-5p represses bone metastasis via inactivating NF-\u03baB signaling in prostate cancer. Mol Ther Nucleic Acids. 2019;18:567\u201379.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"5311_CR92","volume":"7","author":"TK Wilson","year":"2024","unstructured":"Wilson TK, Zishiri OT. Prostate cancer: a review of genetics, current biomarkers and personalised treatments. Cancer Rep. 2024;7(10):e70016.","journal-title":"Cancer Rep"},{"key":"5311_CR93","volume":"2022","author":"C Zhang","year":"2022","unstructured":"Zhang C, Chao F, Wang S, Han D, Chen G. Cell-free DNA as a promising diagnostic biomarker in prostate cancer: a systematic review and meta-analysis. J Oncol. 2022;2022:1505087.","journal-title":"J Oncol"},{"issue":"3","key":"5311_CR94","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ajur.2022.11.002","volume":"10","author":"W He","year":"2023","unstructured":"He W, Xiao Y, Yan S, Zhu Y, Ren S. Cell-free DNA in the management of prostate cancer: Current status and future prospective. Asian J Urol. 2023;10(3):298\u2013316.","journal-title":"Asian J Urol"},{"key":"5311_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094367","author":"S Salciccia","year":"2021","unstructured":"Salciccia S, Capriotti AL, Lagan\u00e0 A, Fais S, Logozzi M, De Berardinis E, et al. Biomarkers in prostate cancer diagnosis: from current knowledge to the role of metabolomics and exosomes. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22094367.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5311_CR96","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0933-3657(00)00053-1","volume":"20","author":"B Zupan","year":"2000","unstructured":"Zupan B, Dem\u0161ar J, Kattan MW, Beck JR, Bratko I. Machine learning for survival analysis: a case study on recurrence of prostate cancer. Artif Intell Med. 2000;20(1):59\u201375.","journal-title":"Artif Intell Med."},{"issue":"1","key":"5311_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14436-y","volume":"12","author":"W Zhang","year":"2022","unstructured":"Zhang W, Zhang K. A transcriptomic signature for prostate cancer relapse prediction identified from the differentially expressed genes between TP53 mutant and wild-type tumors. Sci Rep. 2022;12(1):10561. https:\/\/doi.org\/10.1038\/s41598-022-14436-y.","journal-title":"Sci Rep"},{"issue":"7","key":"5311_CR98","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ccell.2021.04.002","volume":"39","author":"BH Kann","year":"2021","unstructured":"Kann BH, Hosny A, Aerts HJWL. Artificial intelligence for clinical oncology. Cancer Cell. 2021;39(7):916\u201327.","journal-title":"Cancer Cell"},{"key":"5311_CR99","doi-asserted-by":"crossref","unstructured":"Caputo A, Maffei E, Gupta N, Cima L, Merolla F, Cazzaniga G et al. Computer-assisted diagnosis to improve diagnostic pathology: A review. Indian J Pathol Microbiol. 2025;68(1). Available from: https:\/\/journals.lww.com\/ijpm\/fulltext\/2025\/01000\/computer_assisted_diagnosis_to_improve_diagnostic.2.aspx","DOI":"10.4103\/ijpm.ijpm_339_24"},{"issue":"1","key":"5311_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000039","volume":"2","author":"O Bratt","year":"2023","unstructured":"Bratt O, Auvinen A, Arnsrud Godtman R, Hellstr\u00f6m M, Hugosson J, Lilja H, et al. Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps. BMJ Oncol. 2023;2(1):e000039.","journal-title":"BMJ Oncol"},{"issue":"3","key":"5311_CR101","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers and surrogate","year":"2001","unstructured":"Biomarkers and surrogate. endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"5311_CR102","doi-asserted-by":"crossref","unstructured":"Patel DM. Chapter 13 - Ethical considerations in biomarker research and application. In: Prabhakar PKBTTP of CB, editor. Elsevier; 2025. pp. 275\u201383. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780443292798000132","DOI":"10.1016\/B978-0-443-29279-8.00013-2"},{"key":"5311_CR103","doi-asserted-by":"crossref","unstructured":"Micheel CM, Nass SJ, Omenn GS, editors. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington (DC); 2012.","DOI":"10.17226\/13297"},{"issue":"2","key":"5311_CR104","volume":"97","author":"S Vatrano","year":"2025","unstructured":"Vatrano S, Pepe P, Pepe L, Vella N, Alario C, Chiarand\u00e0 A, et al. {BRCA} mutations and prostate cancer: should urologist improve daily clinical practice? Arch Ital Urol Androl. 2025;97(2):13635.","journal-title":"Arch Ital Urol Androl"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05311-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05311-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05311-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:03:21Z","timestamp":1784693001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05311-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5311"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05311-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a review and does not involve human participants or animal studies.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1060"}}